[1] Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev, 2019: 20-28.
[2] Saffo S, Taddei T H. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digest Dis Sci, 2019, 64(4): 1016-1029.
[3] Shlomai A, de Jong YP, Rice CM. Virus associated malignan- cies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol, 2014, 26: 78-88.
[4] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
[5] Elkhoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet, 2017, 389(10088): 2492-2502.
[6] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
[7] Cheng AL, Qin S, Ikeda M, et al. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol, 2019.
[8] Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol, 2017, 35(34): 3807-3814.
[9] Postow MA, Sidlow R, Hellmann MD, et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. New Engl J Med, 2018, 378(2): 158-168.
[10] Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol, 2020, 72(2): 320-341.
[11] Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol, 2020, 72(2): 320-341.
[12] Haanen JB, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol,2017,28(suppl_4):iv119-iv142.
[13] Mitchell KA, Kluger HM, Sznol M, et al. Ipilimumab-induced Perforating Colitis. J Clinical Gastroenterol, 2013, 47(9): 781-785.
[14] Illouz F, Drui D, Caron P, et al. Expert opinion on thyroid complications in immunotherapy.Ann Endocrinol (Paris),2018,79(5):555-561.
[15] Faje AT. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary, 2016, 19(1): 82-92.
[16] Wanchoo R, Karam S, Uppal NN, et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol, 2017, 45(2): 160-169.
[17] Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol, 2016, 28(2): 377-385.
[18] Calvo R. Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. Front Pharmacol, 2019, 10:454.
[19] Jain V, Bahia J, Mohebtash M, et al. Cardiovascular Complications Associated With Novel Cancer Immunotherapies. Curr Treat Options Cardiovasc Med, 2017, 19(5): 36-36.
[20] De Martin E, Michot J, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol, 2018, 68(6): 1181-1190.
[21] Chmiel KD, Suan D, Liddle C, et al. Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. J Clin Oncol, 2011, 29(9):e237-40.
[22] Gardiner DF, Lalezari J, Lawitz E, et al. A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS One, 2013, 8(5).
[23] Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clinl Invest, 1992, 89(1): 87-96.
[24] Sangro B, Gomezmartin C, La Mata MD, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol, 2013, 59(1): 81-88.
[25] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet, 2017, 389(10064): 56-66.
[26] Cheng A, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 307-319.
[27] De Martin E, Michot J, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol, 2018, 68(6): 1181-1190. |
